SOLID TUMOR

This early-phase study tested the safety of combining multiple cancer drugs (niraparib, TSR-022, bevacizumab, chemotherapy, and TSR-042) in 60 adults with advanced or metastatic solid tumors, including lung cancer. The goal was to find safe doses for future larger studies. The tr…

This study tested whether combining several immunotherapy drugs could help people with advanced prostate cancer that no longer responds to hormone therapy. 59 adults received different combinations of a vaccine and other immune-boosting drugs. The goal was to see if these combina…

This early-phase study tested a new drug called TPST-1495, alone or with another drug (pembrolizumab), in 89 people with advanced solid tumors (like colorectal, lung, or head and neck cancer) that had stopped responding to standard treatments. The main goal was to find the safest…

This early study tested a new treatment called QH104 for people with solid tumors that have spread to the lining of the brain (meningeal metastases). The treatment uses specially engineered immune cells (B7H3 CAR-γδ T cells) injected directly into the fluid around the brain. Only…

This early-stage study tested a drug called ALRN-6924 in 142 people with advanced solid tumors or lymphomas that have a normal p53 gene. The main goals were to check safety and find the best dose. Researchers also looked for signs that the drug could shrink tumors. The study is n…

This study tested a new drug called HMPL-453 tartrate, alone or with chemotherapy or another drug, in 190 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if the drug could shrink tumors or slow thei…

This study tested a combination of three drugs (afuresertib, sintilimab, and chemotherapy) in 22 adults with solid tumors like lung, cervical, or stomach cancer that had stopped responding to prior immunotherapy. The goal was to find the safest dose and see if the combo could shr…

This early-stage study tested a new drug called LP-118 in 68 people with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. LP-118 works by blocking certain proteins that…

This early-phase trial tested an experimental drug called CUDC-907 in 26 children and young adults (ages 1-21) whose solid tumors, brain tumors, or lymphoma had stopped responding to standard treatments. The main goal was to find safe dosing and identify side effects. Researchers…

This study tested a precise type of radiation called proton beam therapy for people with cancer that spread to the liver. 92 adults with 1 to 4 liver tumors received this treatment. The goal was to see if it could stop tumor growth and cause fewer side effects than standard radia…

This study tested a new experimental drug called JAB-BX102, given alone or with another cancer drug (pembrolizumab), in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose, while also…

This early-phase study tested an experimental drug called RC108-ADC in 67 adults with advanced solid tumors that have a specific protein called c-Met. The main goals were to check the drug's safety and find the best dose. Researchers also looked at whether the drug could shrink t…

This early-stage study tested a new drug (S095029) alone and with another drug (Sym021) in 41 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and side effects. The study was stopped early for business reasons…

This early-phase study tested a new immune cell treatment called PD-L1 t-haNK in 16 adults with advanced solid cancers that had spread or could not be removed. The main goals were to check safety, find the best dose, and see if the treatment could shrink tumors. The approach uses…

This early-phase study tested a new drug called boserolimab, given alone or with pembrolizumab, in 182 adults with advanced solid tumors (including lung and breast cancers). The main goals were to check safety and how the drug moves through the body. Participants received treatme…

This study tested a new drug combination (MK-4280A) in people with certain skin cancers (cutaneous squamous cell carcinoma) or endometrial cancer. The goal was to see if the treatment could shrink or eliminate tumors. 163 participants received either the combination or a standard…

This early-phase trial tested two experimental drugs, BNT152 and BNT153, in 86 adults with advanced solid tumors that had spread or could not be removed and had no standard treatment options. The main goal was to check safety and find the right dose. Researchers also looked for s…

This study tested a drug called utidelone in 126 people with advanced solid tumors (like stomach, pancreatic, or ovarian cancer) that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors and how safe it was. The trial is complete, but…

This early-stage study tested a new drug, ZN-c3 (Azenosertib), in 274 adults with solid tumors. The main goals were to find a safe dose and see if the drug can shrink tumors. The study is now complete, and results will help decide if further testing is needed.

This early-stage study tested an experimental oral drug called Q702 in 51 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects, while also looking for signs that the drug might shr…

This early-phase trial tested a new drug called FS1502 in 161 adults with advanced HER2-positive solid tumors or breast cancer that had stopped responding to standard treatments. The main goals were to check the drug's safety, find the best dose, and see if it shrinks tumors. Res…

This early-phase study tested a new drug called HCW9218 in 18 people with advanced solid tumors (except pancreatic and brain cancers) who had already tried at least two other treatments. The drug is designed to both activate the immune system and block signals that help tumors gr…

This study tested an experimental drug called RC88 in 198 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The trial is now complete, but results have not been released …

This early-stage trial tested a modified virus called TILT-123 in 32 people with advanced solid tumors that had not responded to standard treatments. The virus is designed to infect and kill cancer cells while also boosting the immune system. The main goal was to check safety and…

This early-phase study tested a new drug called SAIL66 in 22 adults with advanced solid tumors that have a specific protein (CLDN6). The main goals were to check safety, find the right dose, and see if the drug can shrink tumors. Participants received the drug by infusion, and re…

This early-phase study tested the safety of a new antibody drug called HH-101 in 12 adults with advanced solid tumors that had not responded to other treatments. The main goal was to see what side effects occurred and find a safe dose. Researchers also looked for early signs that…

This study tested a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 37 Chinese patients whose advanced solid tumors had not responded to prior treatment. The main goals were to check safety and see if the drugs could shrink tumors. While the treatment aims to…

This study tested a new drug, IBI129, in 180 adults with advanced solid tumors that couldn't be removed by surgery. The goal was to find the safest dose and see if the drug can shrink tumors. It was an early-phase trial to gather information on safety and effectiveness.

This early-phase study tested a new imaging agent called 68Ga-NOTA-SNA002 in 17 adults with solid tumors. The agent was injected into the bloodstream to see how safe it is and how it spreads in the body using PET scans. The goal was to understand its safety and imaging properties…

This early-phase study tested a treatment for people with advanced lung cancer that blocks the airways. Doctors injected a light-sensitive drug into the blood, then used a laser to activate it inside the tumor, aiming to shrink it and relieve symptoms. The study included 19 adult…

This study looked at how the drug tuvusertib is absorbed, broken down, and removed from the body in 12 people with advanced solid tumors. Participants received a special radioactive tracer to track the drug. The main goal was to understand the drug's path in the body, not to trea…

This study tested whether a 10 mg and a 20 mg capsule of an experimental drug called IMP4297 are processed the same way in the body. It involved 36 healthy Chinese adults who took a single dose of each strength on separate days. The goal was to gather information on how the drug …

This study tested whether using an electronic diary (app) helps cancer patients take their oral medications more consistently than a paper diary. 124 adults with solid tumors or blood cancers participated. Researchers compared pill counts between the two groups to see which metho…

This study followed 150 adults with solid tumors who were starting a type of immunotherapy called immune checkpoint inhibitors. Researchers collected data on side effects during each treatment session and asked patients to fill out questionnaires. The goal was to better understan…

This study looked at how a drug called IMP4297, being developed for solid tumors, is absorbed, broken down, and removed from the body. Six healthy Chinese men took a single dose, and researchers measured the drug in their blood, urine, and stool. The goal was to understand the dr…

This study looked at how often a muscle enzyme called CPK increases in people with solid tumors who are taking a type of targeted therapy called tyrosine kinase inhibitors (TKIs). Researchers measured CPK levels in routine blood tests of 154 patients. They also checked if muscle …

This study tested whether a 10 mg and a 20 mg capsule of the experimental drug IMP4297 are processed similarly by the body. It involved 28 healthy Chinese adults who took a single dose of each strength on separate days. The goal was to check bioequivalence, not to treat any disea…

This study looked at how common frailty is among people aged 70 and older with solid tumors who visited a cancer center. Researchers used a short questionnaire called VES-13 to screen patients before their doctor visit. They also checked whether the test results matched the docto…

This pilot study tested whether doctors can safely adjust proton radiation therapy plans while the patient is still on the treatment table. Ten adults with solid tumors participated. The goal was to see if this real-time adjustment is practical and safe enough to study in a large…